Imaging innovators partner to create skin tech that test efficacy of nutritional bioactives
24 Aug 2023 --- Solabia subsidiary BioActor and Pixience, a digital dermatoscope technology manufacturer, have joined forces on a new skin imaging technology that tests and validates nutritional bioactives taken for skin health.
“BioActor wants to bring clinically backed innovation to the nutrition industry. We test all our products in scientifically robust human intervention studies, working with partners like Pixience and the department of health and nutrition at Maastricht University,” explains Hans van der Saag, CEO of BioActor.
The technology that will be leveraged has been developed by Pixience. Specifically, it is a skin image-capturing device (C-Cube) and image analysis software (QuickScale) that evaluates several skin health parameters, including the evaluation of 3D images.
Nutritional actives for skin health
The partnership states each company’s specializations work synergistically to scale the new platform. Bioactor, in particular, clinically validates the health effects of natural compounds.
The Netherlands-based firm specializes in developing and supplying proprietary bioactive formulations to the health and sports nutrition industry. Its primary focus areas are the gut microbiome, brain health, energy and vitality and skin health.
“Pixience has developed a best-in-class skin imaging and analysis technology that will allow us to further improve our skin health for a nutrition platform,” van der Saag notes.
BioActor and Pixience are creating a skin health for nutrition platform using proprietary skin imaging technology.
Bioactor is tasked with creating the C-Cube Clinical Edition. It will carry out the beta testing of the edition.
Meanwhile, Pixience will deliver technical assistance for skin image analysis in new clinical studies on nutrition.
“We initially developed our C-Cube and QuickScale suite of technologies for evaluating topical cosmetic products,” says Sebastien Mangeruca, CEO of Pixience.
“BioActor’s experience in running clinical studies for nutrition and its active program around nutrition and skin health makes them an ideal partner for testing and validating our C-Cube Clinical Edition for nutrition studies.”
Clinically validated products
Earlier this month, BioActor unveiled Naxus, a clinically validated arabinoxylan extract derived from wheat endosperm. The prebiotic ingredient has benefits for microbiota composition, glycemic control and satiety. Arabinoxylan is a naturally occurring polysaccharide in whole grains, vegetables and fruits.
A recent study reveals that incorporating Naxus into food can support a natural approach to weight management via microbiome modulation.
Edited by Inga de Jong
